CLAIMS

1. A pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1λ^6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, and a water-swellable substance, wherein the water-swellable substance is ~~one, or two or more selected from the group consisting of a polymer compound obtained by condensation polymerization of β-glucose, a polymer compound obtained by condensation polymerization of α-glucose, and a polymer compound having a pyrrolidone functional group~~ low substituted hydroxypropylcellulose.

~~2. The pharmaceutical composition for oral administration according to claim 1, wherein the water-swellable substance is one, or two or more selected from the group consisting of:~~
~~i) carmellose, carmellose calcium, croscarmellose sodium, and low substituted hydroxypropylcellulose, which are the polymer compounds obtained by condensation polymerization of β-glucose,~~
~~ii) corn starch, potato starch, rice starch, partially pregelatinized starch, and pregelatinized starch, which are the polymer compounds obtained by condensation polymerization of α-glucose, and~~
~~iii) crospovidone, which is the polymer compound having a pyrrolidone functional group.~~

~~3. The pharmaceutical composition for oral administration according to claim 2, wherein the water-swellable substance is the polymer compound obtained by condensation polymerization of β-glucose, and the polymer compound obtained by condensation polymerization of β-glucose is one, or two or more selected from the group consisting of carmellose, carmellose calcium, croscarmellose sodium, and low substituted hydroxypropylcellulose.~~

~~4. The pharmaceutical composition for oral administration according to claim 3, wherein the polymer compound obtained by condensation polymerization of β-glucose is low substituted hydroxypropylcellulose.~~

~~5. The pharmaceutical composition for oral administration according to claim 2, wherein the water-swellable substance is the polymer compound obtained by condensation polymerization of α-glucose, and the polymer compound obtained by condensation polymerization of α-glucose is one, or two or more selected from the group consisting of corn starch, potato starch, rice starch, partially pregelatinized starch, and pregelatinized starch.~~

~~6. The pharmaceutical composition for oral administration according to claim 2, wherein the water-swellable substance is the polymer compound having a pyrrolidone functional group, and the polymer compound having a pyrrolidone functional group is crospovidone.~~

~~7. The pharmaceutical composition for oral administration according to claim 2, wherein the water-swellable substance is one, or two or more selected from the group consisting of low substituted hydroxypropylcellulose, corn starch, and crospovidone.~~

~~8~~2. The pharmaceutical composition for oral administration according to ~~any one of claims 1 to 7~~ claim 1, wherein the water-swellable substance with respect to a weight of 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1λ^6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof is 20% by weight to 6000% by weight.

~~9~~3. The pharmaceutical composition for oral administration according to any one of claims 1 ~~to 8~~ and 2, wherein the pharmaceutical composition for oral administration is selected from the group consisting of a tablet, a capsule, a granule, and a powder.

~~10~~4. Use of a water-swellable substance in the manufacture of a stable pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1λ^6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, wherein said water-swellable substance ~~being one, or two or more selected from the group consisting of low substituted hydroxypropylcellulose, corn starch, and crospovidone~~ is low substituted hydroxypropylcellulose.